Shan Xiaoxiao, Li Dawei, Yin Huihui, Tao Wenwen, Zhou Lele, Gao Yu, Xing Chengjie, Zhang Caiyun
Anhui Academy of Chinese Medicine, Anhui University of Chinese Medicine, Hefei 230012, China.
Center for Xin'an Medicine and Modernization of Traditional Chinese Medicine of IHM, Grand Health Research Institute of Hefei Comprehensive National Science Center, Anhui University of Chinese Medicine, Hefei 230012, China.
Int J Mol Sci. 2025 Jan 30;26(3):1207. doi: 10.3390/ijms26031207.
Nuclear receptors (NRs) are ligand-activated transcription factors that regulate a broad array of biological processes, including inflammation, lipid metabolism, cell proliferation, and apoptosis. Among the diverse family of NRs, peroxisome proliferator-activated receptors (PPARs), estrogen receptor (ER), liver X receptor (LXR), farnesoid X receptor (FXR), retinoid X receptor (RXR), and aryl hydrocarbon receptor (AhR) have garnered significant attention for their roles in neurodegenerative diseases, particularly Alzheimer's disease (AD). NRs influence the pathophysiology of AD through mechanisms such as modulation of amyloid-beta (Aβ) deposition, regulation of inflammatory pathways, and improvement of neuronal function. However, the dual role of NRs in AD progression, where some receptors may exacerbate the disease while others offer therapeutic potential, presents a critical challenge for their application in AD treatment. This review explores the functional diversity of NRs, highlighting their involvement in AD-related processes and discussing the therapeutic prospects of NR-targeting strategies. Furthermore, the key challenges, including the necessity for the precise identification of beneficial NRs, detailed structural analysis through molecular dynamics simulations, and further investigation of NR mechanisms in AD, such as tau pathology and autophagy, are also discussed. Collectively, continued research is essential to clarify the role of NRs in AD, ultimately facilitating their potential use in the diagnosis, prevention, and treatment of AD.
核受体(NRs)是配体激活的转录因子,可调节广泛的生物过程,包括炎症、脂质代谢、细胞增殖和凋亡。在多样的核受体家族中,过氧化物酶体增殖物激活受体(PPARs)、雌激素受体(ER)、肝脏X受体(LXR)、法尼醇X受体(FXR)、视黄酸X受体(RXR)和芳烃受体(AhR)因其在神经退行性疾病,特别是阿尔茨海默病(AD)中的作用而备受关注。核受体通过调节淀粉样β蛋白(Aβ)沉积、调控炎症途径以及改善神经元功能等机制影响AD的病理生理过程。然而,核受体在AD进展过程中具有双重作用,一些受体可能会加重病情,而另一些则具有治疗潜力,这给它们在AD治疗中的应用带来了严峻挑战。本综述探讨了核受体的功能多样性,强调了它们在AD相关过程中的参与情况,并讨论了以核受体为靶点的治疗策略的前景。此外,还讨论了关键挑战,包括精确识别有益核受体的必要性、通过分子动力学模拟进行详细的结构分析以及进一步研究核受体在AD中的机制,如tau病理和自噬。总的来说,持续的研究对于阐明核受体在AD中的作用至关重要,最终有助于它们在AD诊断、预防和治疗中的潜在应用。